Of all the promises President Donald Trump made for theearly part of his term, controlling stinging drug prices might have seemed theeasiest to achieve.

An angry public overwhelmingly wants change in an easilyvilified industry. Big pharma’s recent publicity nightmare includedthousand-percent price increases and a smirking CEO who said, “I liken myself to therobber barons.” Even powerful members of Congress from both partieshave said that drug prices are too high.

But any momentum to address prescription drug costs — a problemthat a large number of Americans now believegovernment should solve — has been lost amid rancorous debates over replacing Obamacare and stalled byroadblocks erected via lobbying and industry cash.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.